A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
Molnlycke Health Care AB · NCT05588583
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 68
- US sites recruiting
- 4
- Study start
- October 31, 2022
- Record last updated
- April 20, 2023
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to follow the progress of wounds in those with venous leg ulcers and diabetic foot ulcers while using an absorbent dressing called Mepilex Up. The main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit.
Participants will be asked to wear Mepilex Up dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.
Being studied: Mepilex Up
Conditions: Wounds; Wound of Skin; Wound Leg; Wound; Foot; Diabetic Foot Ulcer; Venous Leg Ulcer
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Signed consent to participate (including consent for digital imaging)
- Adult aged ≥18 years
- Diagnosed with a chronic, exuding VLU or DFU
- Exudate amount moderate to large
- Wound size from 3 cm2 to 30 cm2 for VLU and ≥1 cm2 for DFU, as determined by the clinician
- For VLU: ABPI (within 3 months) > 0.7. If ABPI > 1.4, then big toe pressure > 60 mmHg is required or an alternative measurement verifying normal distal arterial flow
- For VLU: Willing to be compliant with compression therapy
Exclusion Criteria
- Infected ulcer according to the judgment of the investigator defined as any wound condition requiring the prescription or continuation of systemic antibiotic therapy at enrollment
- Circumferential wound
- Known allergy/hypersensitivity to the materials of the dressing
- Patients participating in the DIPLO NBF study
- Use of wound fillers
Recruiting US locations
Center for Clinical Research, Inc.
Castro Valley, CA 94546
Site contact: Gayana Sarkisova, CCRC · 800-363-1069 · gayana@ccr-trials.com
Felix Sigal, DPM
Los Angeles, CA 90010
Site contact: Maira Jackson, MA · maira@lafootpain.com
University of Miami
Miami, FL 33125
Site contact: Aliette Espinosa · 305-689-3376 · a.espinosa2@med.miami.edu
Serena Group Research Institute
Pittsburgh, PA 15222
Site contact: Laura Serena · 412-335-0764 · lserena@serenagroups.com
Study contacts (from the official record)
- Janet Kandrevas, MD, MS · 734-358-2174 · janet.kandrevas@molnlycke.com
- Andrea Picchietti, MS, CCRA · 260-258-3879 · andrea.picchietti@molnlycke.com
Similar studies in California
All diabetes studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
TIXiMED, Inc.
- Location
- Chula Vista, CA
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Regeneron Pharmaceuticals
- Location
- Glendale, CA
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of…
AstraZeneca
- Location
- Glendale, CA + 3 other US sites
- Eligibility basics
- Ages 18–75